CTLA4 and hypophysitis: First, ICI-related pituitary hypophysitis is mainly reported to be secondary to CTLA-4 inhibitors such as ipilimumab, and the use of only one patient on a specific ICI in our cohort may have limited the identification of hypophysitis.